Abstract
The link between ethnicity, deprivation and health inequalities is well-established. The relationship between ethnicity and cancer is more complex and influenced by a variety of socio-economic, cultural and physiological factors. Understanding the relationship between ethnicity and patient care indicators for specific cancer types is vital if NHS England is to meet the UK government’s stated priority to reduce health inequalities as it recovers from COVID-19.
This paper explores the impact of ethnicity on clinical severity, treatment costs and a range of patient activity indicators across three cancer types – chronic lymphocytic leukaemia, multiple myeloma and prostate cancer.
The paper uses a dataset derived from the Hospital Episodes Statistics (secondary care) database covering 2016/17 to 2020/21,. This enabled the differential impact of the pandemic on ethnic minority patients to be considered. The data was aggregated by ethnicity and deprivation quintile at a national and Integrated Care System (ICS) level. Clinical severity was proxied using co-morbidity and complications (CC) scores. Multivariate linear regression (OLS) models were used to explore the associations with ethnicity.
Black and South Asian patients CC scores were 12.2% and 15.8% higher than the population average (4.1). Controlling for socio-economic deprivation, South Asian patients had higher average clinical severity (+0.57, p<0.01). In addition, ICSs with large South Asian populations were associated with higher CC scores (+0.69, p<0.01). Treatment costs were higher for Black prostate cancer patients with interventions (+£842, p<0.001) and South Asian multiple myeloma patients (+£1686, p<0.001). Both Black and South Asian patients tend to have more spells in hospital. COVID-19 saw total inpatient admissions fall by 18.9%. Black and South Asian inpatient admissions fell by 1.9 and 2.9 percentage points more than the national average respectively. Average clinical severity increased by 7.1% with the largest increase amongst South Asian (+11.5%) and Black (+8.1%) patients.
The higher clinical severity in South Asian patients and higher treatment costs in Black patients observed in this study are not accompanied by significant variations in patient activity indicators, which may point to drivers associated with delays to diagnosis or barriers to access to primary care.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was fully-funded by Janssen UK (https://www.janssen.com/uk/). An external provider, Interpretive Economics (SW) was commissioned to produce the paper by Janssen-Cilag Ltd (UK), a subsidiary of Johnson and Johnson. All other contributing authors were employees of Johnson and Johnson (PFA, RS, GL). These authors were involved in the initial study design, provided feedback on the manuscript and decision to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
The database analysed in this paper was acquired under license from Wilmington Healthcare Ltd. The terms of the license do not permit the reproduction of the database. The database is based on the Hospital Episode Statistics (HES) available from NHS Digital or Wilmington Healthcare. Wilmington Healthcare Ltd. can be contacted by telephone on 0845 121 3686, by e-mail at client.services{at}wilmingtonhealthcare.com or by visiting www.wilmingtonhealthcare.com. The data is based on the following ICD-10 code C911 - Lymphoid leukaemia C900 - Multiple myeloma and malignant plasma cell neoplasms Multiple myeloma C61X - Malignant neoplasm of prostate The following HRG Groups: - Chronic Lymphocytic Leukaemia, including Related Disorders - Plasma Cell Disorders - Kidney, Urinary Tract or Prostate Neoplasms, with Interventions - Kidney, Urinary Tract or Prostate Neoplasms, without Interventions Wilmington Healthcare extracted the following aggregated tables for the fiscal years 2020/2021, 2019/2020, 2018/2019, 2017/2018, 2016/2017. Tables: "Population data: Population breakdown by National and ICS level for ethnic groups. ICS Codes & Map: BAME % of Total Population Summary data: National and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis by fiscal year and for all 5 fiscal years combined Summary data by ethnicity: National and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis by ethnicity and fiscal year and for all 5 fiscal years combined Summary data by age group: National and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis by age group for all 5 fiscal years combined Summary data by gender: National and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis by gender for all 5 fiscal years combined Summary data by IMD: National and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis by deprivation decile and quintile (using Lower Layer Super Output Area (LSOA) of the patient's residence) for all 5 fiscal years combined Summary data by ethnicity IMD: National level and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis by ethnicity and deprivation decile (using Lower Layer Super Output Area (LSOA) of the patient's residence) for all 5 fiscal years combined" "HRG data: National and ICS level inpatient activity for patients with a haematology, immunology or oncology diagnosis by year, HRG grouping and average CC score (see HRG Codes tab for details of codes used). The average CC score is calculated from the derived CC score (the mid-point of score ranges or the known value for scores without ranges, e.g. 15+). The average normalised CC score have been normalised on a 1-10 scale. HRG data by ethnicity: National and ICS level inpatient activity for patients with a haematology, immunology or oncology diagnosis by year, ethnicity, HRG grouping, average CC score and average normalised CC score. HRG data by IMD : National and ICS level inpatient activity for patients with a haematology, immunology or oncology diagnosis by year, deprivation quintile (using Lower Layer Super Output Area (LSOA) of the patient's residence), HRG grouping , average CC score and average normalised CC score. HRG data by ethnicity IMD: National and ICS level inpatient activity for patients with a haematology, immunology or oncology diagnosis by year, deprivation quintile, HRG grouping, average CC score and average normalised CC score." "Normalised data: National and ICS level inpatient and outpatient activity (patients, spells, appointments) for patients with a haematology, immunology or oncology diagnosis by year, normalised by 100,000 population using ONS mid-year population estimates Normalised data by ethnicity: National and ICS level inpatient and outpatient activity (patients, spells, appointments) for patients with a haematology, immunology or oncology diagnosis by year and ethnicity, normalised by 100,000 population using ONS mid-year population estimates for ethnicity and organisation Normalised by gender: National and ICS level inpatient and outpatient activity (patients, spells, appointments) for patients with a haematology, immunology or oncology diagnosis by year and gender, normalised by 100,000 population using ONS mid-year population estimates for gender and organisation Normalised data by age group: National and ICS level inpatient and outpatient activity (patients, spells, appointments) for patients with a haematology, immunology or oncology diagnosis by year and age group, normalised by 100,000 population using ONS mid-year population estimates for age group and organisation " "Procedures data: National and ICS level inpatient activity for patients with a haematology, immunology or oncology diagnosis by year and intervention type (see Procedure Codes tab for details of OPCS codes used for each diagnosis group) Procedures data by ethnicity: National and ICS level inpatient activity for patients with a haematology, immunology or oncology diagnosis by year, intervention type and ethnicity Procedures data by IMD: National and ICS level inpatient activity for patients with a haematology, immunology or oncology diagnosis by year, intervention type and deprivation quintile (using Lower Layer Super Output Area (LSOA) of the patient's residence) Procedures data by ethnicity IMD: National and ICS level inpatient activity for patients with a haematology, immunology or oncology diagnosis by year, intervention type, ethnicity and deprivation quintile (using Lower Layer Super Output Area (LSOA) of the patient's residence)" "Covid data: National and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis for Covid year and 2 year prior average. Absolute and percentage difference between Covid year and 2 year prior average. Covid data by ethnicity: National and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis and ethnicity for Covid year and 2 year prior average. Absolute and percentage difference between Covid year and 2 year prior average. Covid data by age group: National and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis and age group for Covid year and 2 year prior average. Absolute and percentage difference between Covid year and 2 year prior average. Covid data by gender: National and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis and gender for Covid year and 2 year prior average. Absolute and percentage difference between Covid year and 2 year prior average. Covid data by IMD: National and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis by deprivation decile and quintile (using Lower Layer Super Output Area (LSOA) of the patient's residence) for Covid year and 2 year prior average. Absolute and percentage difference between Covid year and 2 year prior average. Covid data by ethnicity IMD: National and ICS level inpatient and outpatient activity for patients with a haematology, immunology or oncology diagnosis by ethnicity and deprivation decile and quintile (using Lower Layer Super Output Area (LSOA) of the patient's residence) for Covid year and 2 year prior average. Absolute and percentage difference between Covid year and 2 year prior average."
